Katherine Talcott, MD, discusses phase 2 VERONA results showing EYP-1901 plus aflibercept reduced supplemental treatment needs in DME, with early vision and anatomy gains and no significant safety signals.
Katherine Talcott, MD
Advertisement
Retina Specialist at the Cole Eye Institute at the Cleveland Clinic
Articles by Katherine Talcott, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
EURETINA 2026: Uveitis or retinitis pigmentosa? Ester Carreño, MD, PhD, on mimics
2
EURETINA 2026: Retinal signs as diagnostic clues to systemic metabolic disease
3
EURETINA 2026: Gene therapy sessions to watch in Vienna
4
MOGENRY earns Japan priority review for inherited retinal dystrophies
5